Alternate estrogen receptors promote invasion of inflammatory breast cancer cells via non-genomic signaling

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Ohshiro, Kazufumi ^a   Schwartz, Arnold M ^a   Levine, Paul H ^a   Kumar, Rakesh ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFIMOXIFENE; ANTIESTROGEN; DIARYLPROPIONITRILE; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA 36; ESTROGEN RECEPTOR BETA; G PROTEIN COUPLED RECEPTOR 30; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; UNCLASSIFIED DRUG; 2,3 BIS(4 HYDROXYPHENYL) PROPIONITRILE; 2,3-BIS(4-HYDROXYPHENYL)-PROPIONITRILE; LIGAND; NITRILE; PHOSPHOPROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; ENZYME ACTIVATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BREAST CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; UPREGULATION; CELL MOTION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL MOVEMENT; ENZYME ACTIVATION; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATORY BREAST NEOPLASMS; LIGANDS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM INVASIVENESS; NITRILES; PHOSPHOPROTEINS; SIGNAL TRANSDUCTION;

EID: 84856248591     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030725     Document Type: Article

References (42)

1. Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH, (2005) Epidemiology of inflammatory breast cancer (IBC). Breast Dis 22: 9-23.
2. Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH, (2005) Trends in inflammatory breast carcinoma incidence and survival: The Surveillance, Epidemiology, and End Results program at the National Cancer Institute. J Natl Cancer Inst 97: 966-975.
3. Kleer CG, van Golen KL, Merajver SD, (2000) Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2: 423-429.
4. Dirix LY, Van Dam P, Prové A, Vermeulen PB, (2006) Inflammatory breast cancer: current understanding. Curr Opin Oncol 18: 563-571.
5. Merajver SD, Weber BL, Cody R, Zhang D, Strawderman M, et al. (1997) Breast conservation and prolonged chemotherapy for locally advanced breast cancer: the University of Michigan experience. J Clin Oncol 15: 2873-2881.
6. Abner AL, Recht A, Eberlein T, Come S, Shulman L, et al. (1993) Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. J Clin Oncol 11: 44-48.
7. Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, et al. (1988) Management of stage III primary breast cancer with primary chemotherapy, surgery and radiation therapy. Cancer 62: 2507-2516.
8. Van Golen KL, Davies S, Wu ZF, Wang Y, Bucana CD, et al. (1999) A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 5: 2511-2519.
9. Kleer CG, Zhang Y, Pan Q, van Golen KL, Wu ZF, et al. (2002) WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene 21: 3172-3180.
10. Kleer CG, Zhang Y, Pan Q, Gallagher G, Wu M, et al. (2004) WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res 6: 110-115.
11. Van den Eynden GG, Van Laere SJ, Van der Auwera I, Merajver SD, Van Marck EA, et al. (2006) Overexpression of caveolin-1 and-2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer Res Treat 95: 219-228.
12. Charafe-Jauffret E, Tarpin C, Viens P, Bertucci F, (2008) Defining the Molecular Biology of Inflammatory Breast Cancer. Semin Oncol 35: 41-50.
13. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, et al. (2005) Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem Biophys Res Commun 336: 1023-1027.
14. Zou Y, Ding L, Coleman M, Wang Z, (2009) Estrogen receptor-alpha (ER-alpha) suppresses expression of its variant ER-alpha36. FEBS Letters 583: 1368-1374.
15. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, et al. (2006) A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci U S A 103: 9063-9068.
16. Lin SL, Yan LY, Liang XW, Wang ZB, Wang ZY, et al. (2009) A novel variant of ER-alpha, ER-alpha36 mediates testosterone-stimulated ERK and Akt activation in endometrial cancer Hec1A cells. Reprod Biol Endocrinol 7: 102-109.
17. Carmeci C, Thompson DA, Ring HZ, Francke U, Weigel RJ, (1997) Identification of a gene (GPR30) with homology to the G protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics 45: 607-617.
18. Filardo E, Quinn J, Pang Y, Graeber C, Shaw S, et al. (2007) Activation of the novel estrogen receptor G protein-coupled Receptor 30 (GPR30) at the Plasma Membrane. Endocrinology 148: 3236-3245.
19. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER, (2005) A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307: 1625-1630.
20. Fraser SP, Ozerlat-Gunduz I, Onkal R, Diss JK, Latchman DS, et al. (2010) Estrogen and non-genomic upregulation of voltage-gated Na(+) channel activity in MDA-MB-231 human breast cancer cells: role in adhesion. J Cell Physiol 224: 527-539.
21. He YY, Cai B, Yang YX, Liu XL, Wan XP, (2009) Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway. Cancer Sci 100: 1051-1061.
22. Ignatov A, Ignatov T, Roessner A, Costa SD, Kalinski T, (2010) Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells. Breast Cancer Res Treat 123: 87-96.
23. Kang L, Zhang X, Xie Y, Tu Y, Wang D, et al. (2010) Involvement of estrogen receptor variant ER-{alpha}36, not GPR30, in nongenomic estrogen signaling. Mol. Endocrinol 24: 709-721.
24. Moriarty K, Kim KH, Bender JR, (2006) Estrogen Receptor-Mediated Rapid Signaling. Endocrinology 147: 5557-5563.
25. Nguyen DM, Sam K, Tsimelzon A, Li X, Wong H, et al. (2006) Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin Cancer Res 12: 5047-5054.
26. Jaiyesimi IA, Buzdar AU, Hortobagyi G, (1992) Inflammatory breast cancer: a review. J Clin Oncol 10: 1014-1024.
27. McCarthy NJ, Yang X, Linnoila IR, Merino MJ, Hewitt SM, et al. (2002) Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res 8: 3857-3862.
28. Lee LM, Cao J, Deng H, Chen P, Gatalica Z, et al. (2008) ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and-negative human breast carcinomas. Anticancer Res 28: 479-483.
29. Deng H, Huang X, Fan J, Wang L, Xia Q, et al. (2010) A variant of estrogen receptor-alpha, ER-alpha36 is expressed in human gastric cancer and is highly correlated with lymph node metastasis. Oncol Rep 24: 171-176.
30. Zhang XT, Kang LG, Ding L, Vranic S, Gatalica Z, et al. (2011) A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells. Oncogene 30: 770-780.
31. Madeo A, Maggiolini M, (2010) Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts. Cancer Res 70: 6036-6046.
32. Ohshiro K, Rayala SK, Williams MD, Kumar R, El-Naggar AK, (2006) Biological role of estrogen receptor beta in salivary gland adenocarcinoma cells. Clin Cancer Res 12: 5994-5999.
33. Zhang G, Liu X, Farkas AM, Parwani AV, Lathrop KL, et al. (2009) Estrogen receptor beta functions through nongenomic mechanisms in lung cancer cells. Mol Endocrinol 23: 146-156.
34. Huang GS, Gunter MJ, Arend RC, Li M, Arias-Pulido H, et al. (2010) Co-expression of GPR30 and ERbeta and their association with disease progression in uterine carcinosarcoma. Am J Obstet Gynecol 203 (242): e1-5.
35. Plante BJ, Yuan L, Lessey BA, Young SL, (2008) Regulation and signaling of the membrane estrogen receptor, GPR30, in human endometrial cells. Reprod Sci 15: 70A.
36. Lin SL, Yan LY, Zhang XT, Yuan J, Li M, et al. (2010) ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways. PLoS One 5: e9013.
37. Vivacqua A, Bonofiglio D, Albanito L, Madeo A, Rago V, et al. (2006) 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30. Mol Pharmacol 70: 1414-1423.
38. Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, et al. (2006) The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 20: 631-646.
39. Li Y, Birnbaumer L, Teng CT, (2010) Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1. Mol Endocrinol 24 (5): 969-980.
40. Paradiso A, Tommasi S, Brandi M, Marzullo F, Simone G, et al. (1989) Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. Cancer 64: 1922-1927.
41. Van den Eynden GG, Van der Auwera I, Van Laere S, Colpaert CG, van Dam P, et al. (2004) Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer. Breast Cancer Res Treat 85: 13-22.
42. Lappano R, Rosano C, De Marco P, De Francesco EM, Pezzi V, et al. (2010) Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells. Mol Cell Endocrinol 320: 162-170.